
In 2007, the Food and Drug Administration requested that manufacturers of all approved zzso contrast agents zzso drugs widely used in magnetic resonance imaging, use nearly identical text in their product labeling to describe the risk of zzso systemic zzso zzso zzso information about zzso risks led to revision of the labeling text for all of these drugs in zzso The present report summarizes the basis and purpose of this zzso approach and describes some of the related challenges, given the evolutionary nature of the zzso risk zzso The zzso approach for presentation of product risk is designed to decrease the occurrence of zzso and to enhance the safe use of zzso in zzso zzso 

